Related Experiment Video
Updated: Mar 6, 2026
09:32
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
15.6K
Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis
1Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Summary
Non-small cell lung cancer (NSCLC) with KRAS mutations show a trend for higher programmed death-ligand 1 (PD-L1) expression. This association was not observed with EGFR or ALK gene alterations.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein.
- PD-L1 expression is a predictive biomarker for immunotherapy response in non-small cell lung cancer (NSCLC).
- The relationship between PD-L1 expression and specific driver gene mutations in NSCLC requires further clarification.
Purpose of the Study:
- To investigate the clinical association between PD-L1 expression and driver gene status in NSCLC.
- To determine if KRAS, EGFR, or ALK mutations influence PD-L1 positivity.
Main Methods:
- Systematic literature search up to October 2015.
- Meta-analysis of odds ratios (ORs) with 95% confidence intervals (CIs) to assess the association.
- Random- or fixed-effects models were employed.
Main Results:
- Nine studies were included in the analysis.
- KRAS-mutant NSCLC showed a higher likelihood of PD-L1 positivity (51% vs. 36%; OR 1.69; p=0.045).
- No significant association was found between PD-L1 expression and EGFR or ALK status.
Conclusions:
- NSCLC with KRAS mutations exhibit a trend towards increased PD-L1 expression.
- PD-L1 expression levels do not appear to be significantly associated with EGFR or ALK mutations in NSCLC.
